Segments (Tables)

12 Months Ended

Dec. 31, 2021

Segment Adjusted EBITDA by reportable segment was as follows:


	Year Ended December 31,
	2021		2020		2019
Biopharmaceuticals	$	(45,754)	$	(35,378)	$	(44,552)
Exemplar	6,898		4,004		(1,586)
Trans Ova	17,420		13,530		(2,836)
All Other	—		—		(3,501)
Segment Adjusted EBITDA for operating segments	$	(21,436)	$	(17,844)	$	(52,475)

Revenues by reportable segment were as follows:


	Year Ended December 31, 2021
	Biopharmaceuticals		Exemplar		Trans Ova		Total
Revenues from external customers	$	922	$	13,345	$	89,606	$	103,873
Intersegment revenues	1,637		—		429		2,066
Total segment revenues	$	2,559	$	13,345	$	90,035	$	105,939


	Year Ended December 31, 2020
	Biopharmaceuticals		Exemplar		Trans Ova		Total
Revenues from external customers	$	21,780	$	10,158	$	71,186	$	103,124
Intersegment revenues	4,797		—		340		5,137
Total segment revenues	$	26,577	$	10,158	$	71,526	$	108,261


	Year Ended December 31, 2019
	Biopharmaceuticals		Exemplar		Trans Ova		All Other		Total
Revenues from external customers	$	6,259	$	6,958	$	68,672	$	4,873	$	86,762
Intersegment revenues	12,908		7		1,361		11		14,287
Total segment revenues	$	19,167	$	6,965	$	70,033	$	4,884	$	101,049

Goodwill by reportable segment was as follows:


	Biopharmaceuticals		Exemplar		Trans Ova		Total
Goodwill
Balances at December 31, 2019	$	17,449	$	20,076	$	16,594	$	54,119


Foreign currency translation adjustments	244		—		—		244
Balances at December 31, 2020	17,693		20,076		16,594		54,363


Foreign currency translation adjustments	(215)		—		—		(215)
Balances at December 31, 2021	$	17,478	$	20,076	$	16,594	$	54,148

The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss from continuing operations before income taxes:


	Year Ended December 31,
	2021		2020		2019
Segment Adjusted EBITDA for reportable segments	$	(21,436)	$	(17,844)	$	(48,974)
All Other Segment Adjusted EBITDA	—		—		(3,501)
Remove cash paid for capital expenditures, net of proceeds from sale of assets, and cash paid for investments in affiliates	5,774		389		11,886
Add recognition of previously deferred revenue associated with upfront and milestone payments	2,034		25,005		14,721
Other expenses:
Interest expense	(18,891)		(18,400)		(17,666)
Depreciation and amortization	(13,761)		(15,042)		(16,142)
Loss from disposals of assets	(614)		(4,375)		(3,018)
Impairment losses	(543)		(920)		(30,810)

Loss on settlement agreement	—		(11,436)		—
Stock-based compensation expense	(13,904)		(19,746)		(15,098)
Adjustment related to accrued bonuses paid in equity awards	—		2,833		—
Equity in net loss of affiliates	(3)		(1,138)		(2,416)
Other	(19)		11		67
Unallocated corporate costs	(33,506)		(37,479)		(46,007)
Eliminations	(2,056)		(5,713)		(14,306)
Consolidated net loss from continuing operations before income taxes	$	(96,925)	$	(103,855)	$	(171,264)

The table below reconciles total segment revenues from reportable segments to total consolidated revenues:


	Year Ended December 31,
	2021		2020		2019
Total segment revenues from reportable segments	$	105,939	$	108,261	$	96,165
Other revenues, including from other operating segments	—		54		9,064
Elimination of intersegment revenues	(2,066)		(5,137)		(14,507)
Total consolidated revenues	$	103,873	$	103,178	$	90,722